Abstract: A securement assembly for a toy includes a support having an insert with a plurality of tabs cooperatively defining a space, the insert being configured to extend into a receptacle of the toy. The securement assembly also includes a stand with an extension configured to extend into the space cooperatively defined by the plurality of tabs so that, in an assembled configuration of the securement assembly, the extension abuts the plurality of tabs to move the plurality of tabs away from one another and into engagement with a wall of the toy defining the receptacle.

Abstract: A method and a device are disclosed for determining data representative of the layout of a road in a two-dimensional Cartesian coordinate system, the coordinate system being associated with a vehicle travelling along the road. To this end, a first set of first points in the Cartesian coordinate system is determined on the basis of data representative of at least one image of the road environment in front of the vehicle. A second set of second points is determined in the Cartesian coordinate system on the basis of mapping data of the road environment of the vehicle. The data representative of the road layout are obtained on the basis of a part of the first points and a part of the second points.

Abstract: A method and a device are disclosed for determining data representative of the layout of a road in a two-dimensional Cartesian coordinate system, the coordinate system being associated with a vehicle travelling along the road. To this end, a first set of first points in the Cartesian coordinate system is determined on the basis of data representative of at least one image of the road environment in front of the vehicle. A second set of second points is determined in the Cartesian coordinate system on the basis of mapping data of the road environment of the vehicle. The data representative of the road layout are obtained on the basis of a part of the first points and a part of the second points.

Abstract: The invention relates to biomarker assays based on protein/peptide biomarkers which show a pronounced differential behaviour between healthy and cancerous sample proteomes e.g. by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the protein biomarkers in serum, plasma or blood itself.

Abstract: The invention relates to biomarker assays based on protein/peptide biomarkers which show a pronounced differential behaviour between healthy and cancerous sample proteomes e.g. by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the protein biomarkers in serum, plasma or blood itself.

Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behavior between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from health

Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healt

Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healt

Abstract: The encephalopathy caused by ifosfamide and similarly acting compounds can be prevented or treated by the administration of methylene blue or another compound which is able to oxidize a reduced flavin moiety. Pyritinol is able to reduce other aspects of ifosfamide toxicity.